MedTrace Logo

Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 800 mg Chewable Tablets in Healthy Volunteers

NCT06552624 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-08-14

No results posted yet for this study

Summary

Comparative study of the pharmacodynamic parameters and pharmacodynamic equivalence (bioequivalence) of drug Antareit 800 mg chewable tablets and drug Riopan 800 mg chewable tablets in healthy volunteers.

Conditions

  • Heartburn
  • Acid-dependent Diseases of the Gastrointestinal Tract
  • Symptomatic Treatment of Gastric and Duodenal Ulcers

Interventions

DRUG

Magaldrate

A dose of T drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day

DRUG

Magaldrate

A dose of R drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day

Sponsors & Collaborators

  • Valenta Pharm JSC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-07
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06552624 on ClinicalTrials.gov